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Although TSH has been suggested to be a proliferative agent for thyrocytes, the effect 
of TSH on human thyroid cells remains controversial. In particular, most of the reported 
studies relied primarily on changes in DNA synthesis but have not included measurement 
of the number of cells. We argue that only a direct count of cell number, demonstrating 
classical exponential expansion, serves as a valid measurement of proliferation. Thus, 
although some data support TSH as a proliferative agent, most do not provide conclu-
sive evidence. To generate conclusive evidence with regard to a proliferative effect of 
TSH in human thyrocytes, we performed various experiments using primary cultures 
of human thyrocytes. In contrast to previous reports, TSH [±insulin-like growth factor 1 
(IGF-1)] did not induce proliferation of thyrocytes under a variety of different conditions. 
However, TSH/IGF-1 cotreatment did upregulate thyroid-specific gene expression 
including thyroglobulin (TG) and TSHR in a manner consistent with cellular differenti-
ation. Evidence for a proliferative effect of TSH has been used to inform the American 
Thyroid Association’s guidelines for the management of thyroid cancer patients, which 
include TSH suppression. While these recommendations are admittedly based on low- 
to moderate-quality evidence, TSH suppression is still widely used. We present data 
that question the consensus view that TSH promotes proliferation of human thyrocytes 
(upon which the American Thyroid Association’s guidelines are based) and suggest that 
additional studies, including randomized controlled trials, are warranted to address this 
important clinical question.
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The thyrotropin (TSH) receptor (TSHR) plays an important role in thyroid physiology and in the 
pathophysiology of thyroid diseases. TSHR is a G-protein coupled receptor that serves as the main 
regulator of development and function of the thyroid. In the adult thyroid gland, TSH, acting through 
TSHR, stimulates the expression of various thyroid-specific genes that lead to the production and 
secretion of thyroid hormones.
Herein, we address the question of whether TSH stimulates proliferation of human thyrocytes. 
Several issues exist with regard to the validity of the current evidence supporting a proliferative effect 
of TSH in human thyroid cells. Most data concerning the effects of TSH on thyroid cell proliferation 
have been reported in studies of various thyroid-derived cell lines of rat origin (FRTL-5, WRT, and PC 
Cl3) as well as primary cultures of dog thyrocytes [reviewed in Ref. (1)]. The consensus view in these 
models is that TSH increases thyrocyte proliferation and that insulin-like growth factor 1 (IGF-1) 
FiGure 1 | tsH in combination with insulin-like growth factor 1 (iGF-1) does not promote proliferation of human thyrocytes in primary culture but 
induces differentiated gene expression. (A) Human thyrocytes were seeded, allowed to attach overnight, then arrested for 3 days in 0.1% bovine serum 
albumin-containing Dulbecco’s modified Eagle’s medium. Cells were then stimulated with the indicated doses of TSH alone or in combination with 100 ng/mL IGF-1. 
The cell count at the time of stimulation was 25,500 ± 6,245 cells. Cells were harvested and counted after 5 days of treatment. Under no culture conditions did TSH 
alone elicit an increase in thyrocyte cell number (data not shown). A portion of the sample was also analyzed for (B) TSHR and (c) thyroglobulin mRNA expression 
using quantitative PCR. Each experiment contained biological duplicates. Data are expressed as mean ± SEM, n = 3 patient donors.
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or high-dose insulin (activating the IGF-1 receptor) acts syner-
gistically with TSH to promote this effect. The ability to translate 
findings from these models to human cells and tissues is unclear, 
and whether TSH stimulates proliferation of human thyroid cells 
remains controversial (2–4). Westermark et al. (2) studied human 
thyrocytes in primary monolayer cultures and found that TSH 
decreased [3H]thymidine incorporation into DNA and decreased 
cell number. Williams et al. (3) studied human thyroid follicular 
cells in monolayer and suspension cultures by measuring [3H]
thymidine incorporation into DNA and by cell cycle progression. 
In monolayer cultures, they found that TSH had no effect on these 
parameters, whereas in suspension cultures, TSH, in the presence 
of growth factors [high doses of insulin or low concentrations 
of fetal bovine serum (FBS)], increased these parameters. Van 
Keymeulen et al. (4) reported that TSH and high doses of insulin 
stimulated DNA synthesis. Overall, reports supporting TSH as a 
mitogenic agent in human cultures indicate that IGF-1 or insulin 
is required for this effect.
Importantly, in the majority of these studies, the effects on 
“proliferation” were demonstrated by measuring incorporation 
of radiolabeled nucleotides into DNA as a purported measure 
of DNA synthesis. However, the definition of cell proliferation is 
“the process that results in an increase of the number of cells… by 
the balance between cell divisions and cell loss through cell death 
or differentiation” (5). Therefore, an increase in DNA synthesis is 
not necessarily an indication of cell proliferation. In our opinion, 
one must measure an increase in cell number to conclude that 
cell proliferation has occurred. If no increase in cell number is 
observed, even if DNA synthesis or the rate of cell cycle progres-
sion were increased, cell proliferation has not occurred.
We studied the effects of TSH on proliferation and differ-
entiation of normal human thyrocytes in primary monolayer 
cultures. This study and experimental protocols were approved 
by and carried out in accordance with the recommendations 
of the NIDDK Institutional Review Board. All patients gave 
written informed consent in accordance with the Declaration 
of Helsinki. Patient materials were received anonymously with 
approval of research activity through the Office of Human 
Subjects Research, National Institutes of Health. Primary 
cultures of human thyrocytes were established, as described 
previously (6). Fibroblast contamination of cultures was low and 
remained as such even following extended propagation in high-
serum media. Cells were propagated/maintained in Dulbecco’s 
modified Eagle’s medium (DMEM), supplemented with 10% 
FBS, 100  U/mL penicillin, and 10  µg/mL streptomycin (Life 
Technologies Corp., Carlsbad, CA, USA) at 37°C in a humidified 
5% CO2 incubator. During continuous propagation in growth 
medium containing 10% FBS, most human thyrocytes exhib-
ited a doubling time between 72 and 96  h. All cultures, once 
established, were verified for thyroid-specific gene expression 
[thyroglobulin (TG), thyroperoxidase, sodium-iodide symporter, 
deiodinase type 2, and TSHR] via quantitative RT-PCR. Cells 
were serum starved using DMEM containing no FBS but 0.1% 
bovine serum albumin (BSA) for 72  h prior to stimulation. 
Cultures were stimulated with 10 mIU/mL bovine TSH (bTSH) 
in combination with 100  ng/mL IGF-1 in DMEM containing 
0.1% BSA or 2.5% FBS. After 5 days, cells were harvested, and 
proliferation was measured by direct cell counting using the 
Vi-CELL Series Cell Viability Analyzer (Beckman Coulter) 
and analyzed for levels of TSHR and TG mRNAs as markers 
of thyrocyte differentiation by a standard RT-PCR method, as 
described previously (6).
We initially conducted a series of experiments stimulating 
thyrocytes with bTSH only in the presence of various levels 
of FBS. Under no culture conditions did TSH alone elicit an 
increase in thyrocyte cell number (data not shown). However, 
IGF-1 is often considered necessary for the mitogenic effects 
of TSH, particularly in human thyrocytes (1), and we could 
not exclude the possibility that our negative results were 
due to this missing permissive factor. Thus, we repeated the 
original experiments using a combination of TSH and IGF-1 to 
stimulate proliferation. Figure 1 illustrates the results of three 
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experiments, each utilizing a unique patient donor culture, in 
which cells were stimulated without or with 10  mIU/mL of 
bTSH and 100  ng/mL of IGF-1 in medium containing 0.1% 
BSA or 2.5% FBS; 20% FBS was included to demonstrate the 
ability of these cultures to proliferate. In these experiments, 
2.5% FBS stimulated a 40% increase in cell number over BSA-
containing media, whereas 20% FBS stimulated 340% increase 
in 5 days; this increase, nearly two doublings, is clear evdience 
of exponential expansion. On the other hand, it is clear that 
TSH +  IGF-1 had no effect on human thyrocyte proliferation 
in the absence of FBS or in the moderate proliferative environ-
ment fostered by the presence of 2.5% FBS. No differences in 
the proportion of fibroblasts in each culture were observed 
under any of the studied conditions. Importantly, the unstimu-
lated levels of both TSHR and TG mRNAs were progressively 
decreased when the cells were incubated in 2.5% and 20% FBS, 
a sign of de-differentiation. Moreover, TSH + IGF-1 stimulated 
increases in TSHR and TG mRNAs in these cells, a sign of dif-
ferenitation, and this effect was inhibited by the inclusion of 
2.5% FBS. Our previously reported data (6) underline the ability 
of TSH and IGF-1 to induce differentiation in thyroid cells, and 
furthermore, demonstrated that cooperativity between TSHR 
and IGF-1R promotes the upregulation of thyroid-specific 
functions of human thyrocytes in primary culture. Our findings 
are consistent with the commonly observed result that differ-
entiation and proliferation are opposing processes—expression 
of differentiated genes is decreased when cells are proliferating, 
and upregulation of cell-specific, differentiated gene expression 
is not accompanied by stimulation of cell proliferation.
In addition to the data presented here, we have performed 
similar experiments in cultures derived from a total of 10 
patient donors utilizing a variety of conditions, including but 
not limited to various additional concentrations of FBS, TSH 
doses ranging from 0.01 to 100 mIU/mL, TSH or IGF-1 in the 
absence of the other ligand, and time points ranging from 3 to 
14 days of stimulation (data not shown). No condition dem-
onstrated a proliferative effect of TSH on human thyrocytes in 
culture. In fact, following 14 days of stimulation, virtually all 
cultures in 20% FBS were completely confluent (having under-
gone 4–5 doublings) and contact inhibited, while cultures in 
BSA or low serum (with or without additional factors includ-
ing TSH) had not undergone even a single doubling. Also 
not shown here, we have not found any proliferative effect of 
TSH (±IGF-1) on three other human thyroid culture models: 
the immortalized normal human thyrocyte line Nthy-ori 3.1 
(7) and two patient-derived follicular thyroid cancer lines, 
FTC-133 (8) and ML-1 (9). This held true even when the TSH 
receptor was overexpressed via adenoviral infection as per 
Ref. (10), although infection did significantly increase TSH-
mediated cAMP generation in these cells. Thus, TSH promotes 
differentiation but does not stimulate proliferation of human 
thyrocytes in culture.
Evidence supporting a proliferative effect of TSH has been 
used to inform the American Thyroid Association’s guidelines 
for the management of thyroid cancer patients, which include 
the suppression of TSH to prevent disease recurrence and/or 
progression (11). The standard of care for differentiated thyroid 
cancer consists of total thyroidectomy, followed by radioiodine 
therapy (RAI) in the subset of patients with intermediate and 
high-risk disease. Long-term management includes levothyrox-
ine treatment with the dose adjusted to achieve specific TSH 
values based on risk level. Currently, TSH suppression below 
0.1 mIU/L is recommended for high-risk patients (Strong rec-
ommendation, Moderate-quality evidence), 0.1–0.5  mIU/L for 
intermediate-risk patients (Weak recommendation, Low-quality 
evidence), and 0.5–2 mIU/L for low-risk patients (Weak recom-
mendation, Low-quality evidence). As indicated in the guidelines, 
these recommendations are based on low- or moderate-quality 
evidence–predominantly retrospective studies with limited 
numbers of patients. Regardless, TSH reduction to these levels 
is a recommended component of thyroid cancer treatment, 
although full TSH suppression is now recommended only for 
high-risk patients. TSH suppression may result in undesirable 
side effects and lower quality of life for the patient while provid-
ing a questionable clinical benefit (12).
Although we would not conclude that the results presented 
herein have direct relevance to the effects of TSH in humans, 
we suggest that the general view that TSH is a human thyrocyte 
proliferating factor be reconsidered. Further clarification, includ-
ing double-blind clinical trials leading to high-quality evidence, is 
necessary to definitively address these concerns.
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